Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma
Long-term follow-up of ibrutinib plus venetoclax showed prolonged efficacy and a well-tolerated safety profile in Japanese patients with R/R MCL.
Authors
- Satoshi Ito
- Hideki Goto (ORCID: https://orcid.org/0000-0001-8361-9973)
- Masahiro Kizaki
- Qianwang Chen (ORCID: https://orcid.org/0000-0002-9616-8873)
- Natsuko Satomi-Tsushita
- Hideyuki Honda
- Koji Izutsu (ORCID: https://orcid.org/0000-0001-9129-8057)
- Koji Kato (ORCID: https://orcid.org/0000-0002-5815-4585)
- Masaki Yamaguchi (ORCID: https://orcid.org/0000-0003-4177-761X)
- Noriko Fukuhara (ORCID: https://orcid.org/0000-0003-2682-2179)
- Tomomi Soshin
- Toko Saito
- Yasuhito Terui
Institutions
- AbbVie (United States) (US)
- Tohoku University Hospital (JP)
- Kyushu University Hospital (JP)
- Ishikawa Prefectural Central Hospital (JP)
- Saitama Medical University Hospital (JP)
- ABB (Japan) (JP)
- Aichi Cancer Center (JP)
- Hokkaido University Hospital (JP)
- Tokyo National Hospital (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- Yamagata University Hospital (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1007/s10147-025-02865-4
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Chugai Pharmaceutical